Amryt Pharma Plc (AMYT) - Financial and Strategic SWOT Analysis Review

November 2021 | 53 pages | ID: A6DB1E8CE73EN
GlobalData

Abstracts

Amryt Pharma Plc (AMYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Amryt Pharma Plc (Amryt) is a biopharmaceutical company which develops and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products include lomitapide for the treatment of adult HoFH and Metreleptin for the treatment of leptin deficiency. The company is also developing a portfolio of pipeline candidates, Oleogel-S10 and AP103 targeting multiple orphan diseases such as epidermolysis bullosa. The company offers its products in the US, Europe, the Middle East and Africa (EMEA). Amryt Pharma is headquartered in London, the UK.

Amryt Pharma Plc Key Recent Developments

Nov 03,2021: Amryt Reports Strong Q3 2021 Results
Nov 03,2021: Amryt Pharma Reports Strong Q3 2021 Results
Oct 20,2021: Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
Oct 19,2021: Amryt announces new patents for Oleogel-S10 and Mycapssa
Sep 13,2021: Amryt Raises Full Year 2021 Revenue Guidance to $220M - $225M

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Amryt Pharma Plc - Key Facts
Amryt Pharma Plc - Key Employees
Amryt Pharma Plc - Key Employee Biographies
Amryt Pharma Plc - Major Products and Services
Amryt Pharma Plc - History
Amryt Pharma Plc - Company Statement
Amryt Pharma Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Amryt Pharma Plc - Business Description
Product Category: Lomitapide
Overview
Performance
Product Category: Metreleptin
Overview
Performance
Product Category: Others
Overview
Performance
Geographical Segment: EMEA
Performance
Geographical Segment: Other
Performance
Geographical Segment: The US
Performance
R&D Overview
Amryt Pharma Plc - Corporate Strategy
Amryt Pharma Plc - SWOT Analysis
SWOT Analysis - Overview
Amryt Pharma Plc - Strengths
Amryt Pharma Plc - Weaknesses
Amryt Pharma Plc - Opportunities
Amryt Pharma Plc - Threats
Amryt Pharma Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, OIL & GAS FINANCIAL DEALS AND ALLIANCES

Amryt Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Amryt Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Amryt Pharma Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Nov 03, 2021: Amryt Reports Strong Q3 2021 Results
Nov 03, 2021: Amryt Pharma Reports Strong Q3 2021 Results
Oct 20, 2021: Amryt to Report Q3 2021 Results and Host Conference Call & Webcast on November
Oct 19, 2021: Amryt announces new patents for Oleogel-S10 and Mycapssa
Aug 06, 2021: Amryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
Jul 12, 2021: Amryt to Report Q2 2021 Results and Host Conference Call & Webcast on August
Jun 28, 2021: Publication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
May 05, 2021: Chiasma Reports First Quarter Financial Results and Announced Agreement to Merge with Amryt
May 05, 2021: Amryt reports record Q1 2021 financial and operating results
Apr 15, 2021: Amryt to Report Q1 2021 Results and Host Conference Call & Webcast on May

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Amryt Pharma Plc, Key Facts
Amryt Pharma Plc, Key Employees
Amryt Pharma Plc, Key Employee Biographies
Amryt Pharma Plc, Major Products and Services
Amryt Pharma Plc, History
Amryt Pharma Plc, Other Locations
Amryt Pharma Plc, Subsidiaries
Amryt Pharma Plc, Key Competitors
Amryt Pharma Plc, Ratios based on current share price
Amryt Pharma Plc, Annual Ratios
Amryt Pharma Plc, Annual Ratios (Cont...1)
Amryt Pharma Plc, Annual Ratios (Cont...2)
Amryt Pharma Plc, Interim Ratios
Amryt Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Amryt Pharma Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Amryt Pharma Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Amryt Pharma Plc, Performance Chart (2016 - 2020)
Amryt Pharma Plc, Ratio Charts
Amryt Pharma Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Amryt Pharma Plc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021